NFGH
Nan Fung Group Holdings Portfolio holdings
AUM
$63.4M
This Quarter Return
+4.35%
1 Year Return
+35.61%
3 Year Return
+215.98%
5 Year Return
–
10 Year Return
–
AUM
$117M
AUM Growth
+$117M
(+0.73%)
Cap. Flow
+$4.9M
Cap. Flow
% of AUM
4.19%
Top 10 Holdings %
Top 10 Hldgs %
62.08%
Holding
41
New
3
Increased
8
Reduced
3
Closed
6
Top Buys
| 1 |
VRNA
Verona Pharma
VRNA
|
$6.18M |
| 2 |
Recursion Pharmaceuticals
RXRX
|
$4.49M |
| 3 |
Rubrik
RBRK
|
$1.59M |
| 4 |
Tourmaline Bio
TRML
|
$817K |
| 5 |
Kymera Therapeutics
KYMR
|
$805K |
Top Sells
Sector Composition
| 1 | Healthcare | 98.3% |
| 2 | Technology | 1.36% |
| 3 | Materials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Illumina
ILMN
$15.8B
| $15.9M | 13.62% | 119,196 | – | – |
|
2
Harmony Biosciences
HRMY
$2.12B
| $12.7M | 10.85% | 368,665 | – | – |
|
3
Oculis Holding
OCS
$844M
| $7.42M | 6.34% | 436,378 | – | – |
|
|
VRNA
4
Verona Pharma
VRNA
$9.16B
| $6.18M | 5.28% | +133,040 | New | +$6.18M |
|
5
Zai Lab
ZLAB
$3.68B
| $6.15M | 5.26% | 235,000 | – | – |
|
6
Mirum Pharmaceuticals
MIRM
$3.71B
| $5.18M | 4.43% | 125,330 +19,230 | +18% | +$795K |
|
7
Merus
MRUS
$4.98B
| $5.05M | 4.32% | 120,038 | – | – |
|
8
Geron
GERN
$893M
| $4.86M | 4.16% | 1,373,550 | – | – |
|
9
Incyte
INCY
$16.5B
| $4.63M | 3.96% | 67,022 -7,000 | -9% | -$483K |
|
|
10
Recursion Pharmaceuticals
RXRX
$2.04B
| $4.49M | 3.84% | +664,610 | New | +$4.49M |
|
11
Xenon Pharmaceuticals
XENE
$2.98B
| $4.18M | 3.58% | 106,680 | – | – |
|
12
Replimune Group
REPL
$422M
| $3.9M | 3.33% | 321,746 +33,900 | +12% | +$411K |
|
|
13
Tourmaline Bio
TRML
$601M
| $3.79M | 3.25% | 187,090 +40,290 | +27% | +$817K |
|
|
ONC
14
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $3.69M | 3.16% | 19,997 -3,025 | -13% | -$559K |
|
15
Soleno Therapeutics
SLNO
$3.6B
| $3.58M | 3.06% | 79,650 +15,700 | +25% | +$706K |
|
16
Madrigal Pharmaceuticals
MDGL
$9.76B
| $3.43M | 2.94% | 11,122 +1,360 | +14% | +$420K |
|
17
Standard BioTools
LAB
$481M
| $3.3M | 2.82% | 1,883,179 | – | – |
|
18
Rhythm Pharmaceuticals
RYTM
$6.85B
| $2.75M | 2.35% | 49,120 | – | – |
|
19
Exelixis
EXEL
$10.1B
| $2.14M | 1.83% | 64,200 | – | – |
|
20
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.89M | 1.62% | 102,984 | – | – |
|
21
Ascendis Pharma
ASND
$11.8B
| $1.87M | 1.6% | 13,600 | – | – |
|
|
22
Rubrik
RBRK
$17.3B
| $1.59M | 1.36% | +24,338 | New | +$1.59M |
|
23
KalVista Pharmaceuticals
KALV
$678M
| $1.31M | 1.12% | 154,522 | – | – |
|
|
24
Kymera Therapeutics
KYMR
$2.95B
| $1.24M | 1.06% | 30,875 +20,000 | +184% | +$805K |
|
|
BCYC
25
Bicycle Therapeutics
BCYC
$511M
| $965K | 0.83% | 68,943 +37,358 | +118% | +$523K |
|